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A B S T R A C T
Background: Austria introduced a school-based gender-neutral human papillomavirus (HPV) immunization
program in February 2014. In order to assure high coverage, factors inﬂuencing acceptance of the vaccine need
to be identiﬁed. In this study we aim to assess parents’ attitude and related socio-demographic factors in
relation to the newly implemented gender-neutral, school-based HPV Immunization program.
Methods: Parents of 4th grade school children in 20 randomly selected primary schools were asked to ﬁll out
questionnaires on socio-demographic factors and on the level of information and attitude towards HPV
infection and HPV vaccine.
Results: A total of 439 parents with 449 vaccine eligible children participated in the study. Fifty nine percent of
vaccine eligible girls and 51.8% of eligible boys received the ﬁrst dose of the vaccine. Fear of side eﬀects and
child being too young for the vaccine were the most commonly cited reasons by parents electing not to let child
receive the vaccine. Children who had received other school-based vaccines have more than ﬁfteen times higher
probability of receiving HPV vaccine. To have received HPV-related information from physicians positively
inﬂuenced vaccine acceptance (OR (95% CI)=1.60 (1.06–2.43)). Higher paternal (fathers’) educational status
signiﬁcantly increased the chances of a male child to be HPV vaccinated (OR (95% CI)=2.45 (1.29–4.78)).
Conclusion: Despite the eﬀorts to provide HPV vaccine free-of-costs and as a school-based program, the study
found that a signiﬁcant proportion of vaccine eligible children failed to receive the vaccine. Involvement front
line physicians and men with higher educational status may be utilised by public health policy makers in the
eﬀort to increase awareness. For a better acceptability of the vaccine, there is a need to consider lifting the age of
“eligibility” for the school-based vaccination program.
1. Background
Human papillomavirus (HPV) infection is a common sexually
transmitted infection peaking in prevalence in adolescence [1]. Most
of these infections are transient and only a certain proportion persists
to lead to high grade lesions and eventually to HPV associated cancers
[2–6].
For the prevention of cervical and other genital neoplasia as well as
genital warts, three vaccines – Gardasil® (quadrivalent vaccine against
HPV types 6, 11, 16 and 18), Gardasil 9® (nonavalent vaccine against
HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58) and Cervarix® (bivalent
vaccine against HPV types 16 and 18) – have been developed and
approved for use [7–9]. Even if the vaccines had been recommended to
young men and women in Austria, free-of-charge immunization
program was started only in 2014 [10]. Starting from the autumn of
2014, fourth grade primary school girls and boys receive two doses of
Gardasil® (0–6 months) as part of school-based immunization pro-
gram. This makes Austria – next to Australia, USA and some parts of
Canada – the ﬁrst country to incorporate men/boys in the routine HPV
immunization program [11].
Estimations from mathematical modelling studies reveal that a
gender-neutral immunization scheme may result in a substantial and
more rapid reduction in the associated disease burden [12]. This goal
of rapid reduction in disease burden can only be reached depending on
the proportion of target population who receive the vaccine. Seen
generally, one of the most important factors aﬀecting the immunization
coverage is the acceptance of the vaccine in the community. Previous
studies in other countries have shown that parents' level of information
and attitude towards HPV vaccine play decisive role in the acceptance
of the vaccine [13–17].
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In Austria - due to the novelty of the program - there are no data on
parental attitudes and acceptance towards HPV vaccine.
With this study, we aim to assess parental factors associated with
decision to let child receive the newly introduced gender-neutral, free-
of-charge, school-based HPV immunization. The results of the survey
will be of high value in evaluating and tackling the possible barriers to
successful coverage of the vaccine at this very early stage of the
program.
2. Methods
2.1. Study design
This is a cross sectional survey on the knowledge, attitude and
practice of parents of primary school children in west Austria on the
newly implemented school-based HPV vaccination program.
2.2. Study population
2.2.1. Study participants
The study participants were parents of a total of 671 fourth grade
school children from 20 primary schools in Tyrol – a region in west
Austria. The schools were selected randomly out of a total of 383
primary schools in the region [18]. The study was conducted in April
2015.
2.2.2. Data collection
After obtaining ethical clearance from the Ethic Committee of the
Medical University of Innsbruck and the regional school inspector,
questionnaires were distributed to the parents via the respective
schools. The information obtained from the questionnaires included
socio-demographic data, awareness on HPV Infection, knowledge and
attitude towards school-based immunizations particularly on HPV
vaccine. School children brought ﬁlled out and sealed questionnaires
back to the schools which subsequently were sent to the study center
(local public health department of Tyrol) via a prepaid post system.
2.2.3. Data analysis
Descriptive analyses of data were conducted. Logistic regression
model was used to compute odds ratios with corresponding 95%
conﬁdence intervals for HPV vaccine acceptance across several socio
demographic variables and other factors associated with awareness on
HPV infection. P-values < 0.05 were considered signiﬁcant.
Statistical analyses were performed in SPSS (Version 20.0. Armonk,
NY: IBM Corp.).
3. Results
A total of 439 study participants with 449 vaccine eligible boys and
girls returned ﬁlled out questionnaires making a total response rate of
67%. Table 1 presents baseline socio-demographic characteristics of
the study participants. Mean age of the study participants was 40.8
(SD=5.7). Majority of the respondents were females/mothers. Majority
are married or live in partnership. Respondents and the respective
partners have comparable educational as well as employment status.
Table 2 shows data on awareness of HPV infection as well as on
HPV vaccine acceptance. Majority of the study participants report to
have heard about HPV and answered correctly, that HPV can cause
cancer in both men and women. Only a quarter believe that HPV causes
cancer only in women. One third of the study participants reported to
have obtained information about HPV vaccine from their general
practitioners or paediatricians whereas the rest received from the
information-leaﬂets prepared by the local health government and sent
out to the schools.
Over 85% of the respondents reported that their children had
received other school-based immunizations. Out of a total of 449 HPV
vaccine eligible children 101 boys (51.8%) and 150 girls (59%) received
the ﬁrst dose of HPV the vaccine (Table 2).
Table 3 presents the odds ratios and 95% conﬁdence intervals (OR
(95% CI)) for factors aﬀecting parents’ decisions to let child receive
vaccine. Having child receive other school-based vaccines was asso-
ciated with over a ﬁfteen-fold higher probability of being vaccinated for
HPV. Parents who report to have heard of HPV were signiﬁcantly more
likely to have child receive the vaccine. Moreover, having obtained
information on HPV vaccine from physicians associated positively with
the decision to accept the vaccine. The association was statistically
signiﬁcant for overall and female child vaccinations.
Educational status of the male partner positively inﬂuenced HPV
vaccine acceptance. This was particularly statistically signiﬁcant for
vaccination of boys whose fathers had reached levels of high school or
above. On the contrary, neither respondents' (women's) educational
status nor other socio-demographic factors like religion, marital,
employment or immigration status showed signiﬁcance on HPV
vaccine acceptance.
The most commonly cited reasons for not having child receive HPV
Table 1
Baseline characteristics of survey respondents (n=439).
Age, years
Mean (SD) 40.8 (5.7)
Respondent, n (%)
Mother 395 (90%)
Father 42 (9.6%)
Number of children
Median (IQR) 2 (2–3)
Married/Partnership, n (%) 380 (85.4)
Religion, n (%)
R. Catholic 331 (74.4)
Muslim 47(10.6)
Education, n (%)
Basic schooling 182 (41.5)
Higher education 257 (58.5)
Partner's education, n (%)
Basic schooling 168 (43.8)
Higher education 216 (56.2)
Employment status, n (%) 340 (76.4)
Partner's employment status, n (%) 336 (82.2)
Migration history, n (%) 47 (10.6)
SD=standard deviation, IQR=interquartal range.
Table 2
Characteristics of survey participants across data relating to HPV infection and HPV
vaccine (n=439).
Heard about HPV, n (%) 380 (85.4)
HPV causes cancer, n (%)
Only in women 106 (23.8)
Only in men 0
Men and women 297 (66.7)
HPV causes no cancer 22 (4.9)
HPV associated illness in the family 66 (14.8)
Source of HPV vaccine information, n (%)
Child's school 415 (93.3)
GP/paediatrician 145 (32.6)
HPV Vaccine eligible children, n (%)
Vaccine eligible boys 195 (41.7)
Vaccine eligible girls 254 (57.9)
HPV Vaccinated children, n (%)
Vaccinated boys 101(51.8)
Vaccinated girls 150 (59)
Accept HPV vaccine latera, n (%)
Yes 48 (32.4)
No 29 (15.4)
Do not know 71 (37.8)
Child vaccinated for other school-based vaccinations, n
(%)
379 (86.3)
HPV=human papillomavirus
a Among non-vaccinated, total number of respondents (n)=148.
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vaccine included, fear of debilitating or temporary side eﬀects, child
being too young for the vaccine, vaccine being too new and lack of
adequate information on the vaccine (Table 4). Approximately ten
percent of the study participants (one ﬁfth of those who refused the
vaccine) reported to be “generally against all vaccines”. About ﬁve
percent of the parents who declined the vaccine gave the reason that
their general practitioner or paediatrician was not convinced about the
necessity of HPV vaccine. Most parents gave a combination of factors;
however, child's age at vaccination was the most commonly cited single
reason for opting out. Separate analysis of data for boys and girls
showed no diﬀerence in the stated argumentations for declining the
vaccine (data not shown).
4. Discussion
The current school-based HPV immunization program in Austria is
designed to eﬃciently oﬀset possible ﬁnancial and logistic barriers that
may interfere with vaccine acceptance. Despite these eﬀorts, however, a
signiﬁcant proportion of the eligible target population, namely 50% of
the boys and 40% of the girls, failed to receive the ﬁrst dose of the HPV
vaccine making the acceptance way below the expected vaccine cover-
age needed for a herd immunity eﬀect [19]. Socio-demographic factors
and factors associated with perception about HPV infection and
vaccination were among the contributing factors.
Previous studies report statistically signiﬁcant association between
parental educational status and HPV vaccine acceptance. Majority of
these reports indicated a paradoxical outcome of higher parental
education having negative eﬀect on HPV vaccination [13–16]. A large
register-based study in Norway based on about 85 000 study partici-
pants noted such an association both for maternal and paternal
educational status, the degree of association being higher for that of
maternal education [20]. These ﬁndings of inverse association are
explained mainly by the fact that educated parents tend to undertake
own internet research making them likely to end up in websites with
unclear and confusing information on HPV or even websites which
clearly condemn the vaccine [21–23]. One can also speculate that
educated parents may be able to perceive HPV as “not-immediately-
life-threatening” and may decide to postpone the vaccination to a later
age, but still before ﬁrst sexual contact.
Our result of paternal (male partners') educational status positively
inﬂuencing HPV vaccine acceptance is in line with another population-
based cohort study from Sweden [24], which showed fathers’ education
at high school or university level to be signiﬁcantly higher among HPV
vaccinated individuals compared to non-vaccinated (relative risk (95%
conﬁdence interval) (RR (CI))=2.75 (2.69–2.81) and 4.31 (4.22–4.4)),
respectively. This study found signiﬁcant association not only for
fathers’ but also for that of mothers' educational status. In our study,
on the contrary, mothers' educational status, showed no statistically
signiﬁcant diﬀerence on HPV vaccine acceptance. Of note, the sig-
niﬁcant inﬂuence of paternal education for vaccination of boys but not
Table 3
Multivariate adjusted* factors aﬀecting parents' decision to have child receive vaccine.
OR (95% CI)
Factors Overall Girls
(n=254)
Boys
(n=195)
Respondents age
(years)
≤40 1 1 1
> 40 1.07 (0.73–1.58) 1.11 (0.67–
1.86)
0.92 (0.52–
1.62)
Number of Children
One or two 1 1 1
Three or more 0.95 (0.78–1.16) 0.62 (0.37–
1.05)
1.50 (0.82
−2.75)
Marital status
Single/divorced 1 1 1
Married/partnership 0.89 (0.51–1.54) 0.99 (0.48–
2.04)
0.69 (0.30–
1.59)
Educational status
Basic/vocation school 1 1 1
High school/university 1.25 (0.84–1.86) 1.37 (0.80–
2.35)
1.20 (0.68–
2.15)
Educ. status (partner)
Basic/vocation school 1 1 1
High school/university 1.75 (1.13–
2.72)†
1.31 (0.73–
2.36)
2.45 (1.29–
4.78)†
Employment status
Non-employed 1 1 1
Employed/own business 1.21 (0.76–1.93) 1.62 (0.85–
3.10)
0.90 (0.47–
1.74)
Employ. Status
(partner)
Non-employed 1 1 1
Employed/own business 1.43 (0.45–4.53) 1.71 (0.24–
12.41)
1.18 (0.29–
4.87)
Immigration status
Non-immigrant 1 1 1
Immigrant 0.57 (0.46–1.58) 0.83 (0.39–
1.74)
0.91(0.31–
2.62)
Vaccinated for other
school-based
vaccines
No 1 1 1
yes 15.8 (6.62–
37.8)†
15.5 (5.26–
44.9)†
18.5 (4.22–
81.2)†
Heard of HPV
No 1 1 1
yes 1.74 (1.10–
2.79)†
1.79(0.97–
3.31)
1.45 (0.70–
3.00)
Respondent's
estmation of HPV
prevalence
HPV infection is rare 1 1 1
HPV infection is common 1.80 (1.20–
2.68)†
1.71 (1.00–
2.90)†
1.69 (0.93–
3.07)
HPV vaccine
information from
physician
No 1 1 1
yes 1.60 (1.06–
2.43)†
1.80 (1.05–
3.10)†
1.22 (0.65–
2.29)
Family history of HPV
related diseases
No 1 1 1
Yes 1.73(0.98–
3.07)
1.40 (0.70–
2.81)
2.20 (0.87–
5.59)
OR=odds ratio, CI=confidence interval, HPV=human papillomavirus
* Adjusted for age of respondents and number of children per family,
† = P > 0.05.
Table 4
Main reasons for NOT having child receive HPV vaccine (n=185).
Reasons, n (%)
Fear of debilitating/permanent side eﬀects 56 (30.2)
Child too young for the vaccine 54 (29.2)
Fear of side eﬀects although temporary 49 (26.5)
Not being adequately informed 42 (22.7)
Discouraging information about the vaccine from internet 40 (21.6)
Generally against all vaccines 37 (20)
Other reasons/Vaccine too new (majority) 33 (17.8)
The vaccine is just a publicity ploy by pharmaceutical company 31(16.8)
Child missed school at the day of vaccination 18 (9.7)
Vaccine unnecessary due to low disease risk 18 (9.7)
Vaccine not eﬀective 15 (8.1)
Child is afraid of needles 14 (7.6)
Wait for vaccine which covers more HPV types 12 (6.5)
Child afraid of getting vaccinated at school 12 (6.5)
Child has allergy 11(5.9)
GP/Paediatrician does not believe it is necessary 10 (5.4)
Other reasons 20 (10.8)
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girls is a unique ﬁnding to our study. Larger population based study
may be needed to further clarify if the observed disparity between
maternal and paternal educational status in our setting is a true
diﬀerence or simply lack of a statistical power.
Further, our results demonstrated that awareness on HPV signiﬁ-
cantly impacted parents’ receptiveness to HPV vaccination. Although
the proportion of parents who reported to have received information on
the vaccine from their physicians was low, these parents were
signiﬁcantly more likely to let child receive the vaccine than those
who had other sources of information. Encouraging physicians to make
use of this encounter to provide information on HPV vaccine may be an
important entry point in the eﬀort to raise HPV vaccine coverage.
Vaccination of eligible children falling into the free-of-charge-
immunization program in the study region is limited to schools
(school-based) and to the local public health oﬃcers in the region
[10]. This exclusion of general practitioners and paediatricians from
providing the vaccine to the eligible group may be the reason why only
a third of the participants got consulted by their physicians. It could be
speculated that physicians may actively recommend the vaccine only if
they also provide it. Studies from other regions with diﬀerent im-
munization guidelines – where also paediatricians vaccinate the
eligible age group – may be needed to assess the signiﬁcance of this
speculation.
Physician-patient encounter may also be used as a platform to deal
with the commonly cited concerns of parents who decline the vaccine.
In our study, “vaccine safety” was the most commonly stated reason for
not having child receive HPV vaccine. Since other sources of informa-
tion, like the web for example, report predominantly on speculated
negative outcomes of vaccines in general and HPV vaccine in parti-
cular, front line physicians' (GPs and paediatricians) active and
competent communication of the issue with their patients is of
paramount importance.
Another major concern parents mentioned in the current study was
“age of child at vaccination”. Almost 30% of parents who refused to let
child receive the HPV vaccine stated that their nine- or ten-year-old
child is too young for the vaccine. Since it is clear that HPV vaccine
prevents sexually transmitted diseases, it may be speculated that
parents ﬁnd it incomprehensible to vaccinate a child for an eﬀect
needed several years later. In addition, an unpublished survey in the
same study region among paediatricians and gynaecologists showed
that about half of the physicians recommended vaccinating children at
or beyond 12 years of age but deﬁnitely before sexual debut. Moreover,
it is not well established if a 2-dose vaccination program provides a
long-lasting protection as the 3-dose program, thereby not (yet)
excluding the issue of a potential need for a booster immunization at
the age where the vaccinees actually need the required eﬀect [25]. The
combination of these factors justiﬁes a consideration to lift the age of
vaccination by few years and yet before sexual debut. According to our
ﬁndings, raising the age may highly likely increase the acceptance rate
because only 15% of the parents clearly declined the vaccine even at a
higher age and because only a minority are generally against all
vaccines.
The chances of receiving HPV vaccine was shown to be more than
ﬁfteen times higher among eligible boys and girls who – according to
the parents – had received other school-based vaccines. This may mean
that barriers to HPV vaccine acceptance are not limited to the concerns
associated with this particular vaccine but to a great extent also to the
existing universal reservation towards all vaccines. Our study found a
non-negligible proportion of the study participants to be generally
against vaccines. This is in line with previous studies in Austria noting
that immunization coverages had been on the decline leading to
ongoing outbreaks in vaccine-preventable childhood diseases [26]
Therefore, public health eﬀorts ﬁghting to tackle barriers to other
childhood and school-based vaccine acceptance in general may also
raise HPV vaccine coverage.
One limitation of our study may be the design of the questionnaire
which was restricted to ﬁnding out the reasons for declining HPV
vaccine but not for accepting it. Explicit factors stated by respondents
for letting child receive vaccine may be important entry-points in
programs initiated to raise awareness. Further limitation of the study
may be the size of the study participants, which may have contributed
to the lacking statistical signiﬁcance in the associations between HPV
vaccine acceptance and some factors which, in other studies, showed
obvious signiﬁcance. However, our study had enough power to
demonstrate some signiﬁcant and unique associations contributing
valuable information to the existing pool of data in this area. Although
the current study is limited to the western region of the country, the
results motivate to undertake further surveys involving other regions of
the country and compare factors inﬂuencing HPV vaccine acceptance.
In conclusion, this study presents the ﬁrst data on the acceptance of
the newly implemented gender-neutral HPV immunization program in
Austria. Only half of the eligible population in this study received the
vaccine. Most commonly cited reasons for vaccine rejection were safety
concerns and age of child at vaccination. Our results established the
importance of some socio-demographic and awareness related factors
in signiﬁcantly inﬂuencing HPV vaccine acceptance despite oﬀsetting
ﬁnancial and logistic barriers through a free-of-charge school-based
immunization policy. Front line physicians and educated men were
found to be important stakeholders in HPV vaccine acceptability in the
region. Educated men's involvement in the community as group or
opinion leaders may be used as a vehicle to transport awareness on
vaccines in general as well as on HPV vaccine in particular. Lifting the
age of eligibility for the school-based HPV immunization program and
involving ﬁrst line physicians in providing the vaccine are key points
worthy of consideration in the eﬀort to increase the vaccine coverage.
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